181 related articles for article (PubMed ID: 25157646)
1. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis.
Berenguer J; Zamora FX; Carrero A; Von Wichmann MA; Crespo M; López-Aldeguer J; Aldámiz-Echevarría T; Montes M; Quereda C; Téllez MJ; Galindo MJ; Sanz J; Santos I; Guardiola JM; Esteban H; Bellón JM; González-García J;
J Acquir Immune Defic Syndr; 2014 Jul; 66(3):280-7. PubMed ID: 25157646
[TBL] [Abstract][Full Text] [Related]
2. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
[TBL] [Abstract][Full Text] [Related]
3. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.
Berenguer J; Alvarez-Pellicer J; Carrero A; Von Wichmann MA; López-Aldeguer J; Mallolas J; Galindo MJ; Van Den Eynde E; Téllez MJ; Quereda C; Tural C; Sanz J; Barros C; Santos I; Pulido F; Guardiola JM; Ortega E; Rubio R; Jusdado JJ; Montes ML; Gaspar G; Barquilla E; Bellón JM; González-García J;
J Hepatol; 2013 Jun; 58(6):1104-12. PubMed ID: 23395690
[TBL] [Abstract][Full Text] [Related]
4. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
[TBL] [Abstract][Full Text] [Related]
5. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
[TBL] [Abstract][Full Text] [Related]
6. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
Labarga P; Fernandez-Montero JV; Barreiro P; Pinilla J; Vispo E; de Mendoza C; Plaza Z; Soriano V
J Viral Hepat; 2014 Jul; 21(7):475-9. PubMed ID: 24750394
[TBL] [Abstract][Full Text] [Related]
7. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S
J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C.
Labarga P; Fernández-Montero JV; de Mendoza C; Barreiro P; Soriano V
Antivir Ther; 2015; 20(1):65-72. PubMed ID: 25105286
[TBL] [Abstract][Full Text] [Related]
9. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
[TBL] [Abstract][Full Text] [Related]
10. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V
Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299
[TBL] [Abstract][Full Text] [Related]
11. Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.
Parise ER; de Oliveira AC; Conceição RD; Amaral AC; Leite K
Braz J Infect Dis; 2006 Apr; 10(2):78-81. PubMed ID: 16878256
[TBL] [Abstract][Full Text] [Related]
12. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
Labarga P; Fernández-Montero JV; López M; Barreiro P; de Mendoza C; Sierra-Enguita R; Treviño A; Soriano V
Antivir Ther; 2014; 19(8):799-803. PubMed ID: 24964405
[TBL] [Abstract][Full Text] [Related]
13. Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients.
Aldámiz-Echevarría T; González-García J; Von Wichmann MA; Crespo M; López-Aldeguer J; Quereda C; Téllez MJ; Galindo MJ; Sanz J; Santos I; Guardiola JM; Bellón JM; Montes M; Berenguer J
Ann Hepatol; 2015; 14(4):464-9. PubMed ID: 26019032
[TBL] [Abstract][Full Text] [Related]
14. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
[TBL] [Abstract][Full Text] [Related]
15. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
ANRS CO13 HEPAVIH Cohort
AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
[TBL] [Abstract][Full Text] [Related]
16. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C.
Myers RP; Patel K; Pianko S; Poynard T; McHutchison JG
J Viral Hepat; 2003 Jan; 10(1):16-22. PubMed ID: 12558907
[TBL] [Abstract][Full Text] [Related]
17. Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection.
Martin-Carbonero L; de Ledinghen V; Moreno A; Maida I; Foucher J; Barreiro P; Romero M; Satta G; Garcia-Samaniego J; Gonzalez-Lahoz J; Soriano V
J Viral Hepat; 2009 Nov; 16(11):790-5. PubMed ID: 19413693
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251
[TBL] [Abstract][Full Text] [Related]
19. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3.
Barreiro P; Martín-Carbonero L; Núñez M; Rivas P; Morente A; Simarro N; Labarga P; González-Lahoz J; Soriano V
Clin Infect Dis; 2006 Apr; 42(7):1032-9. PubMed ID: 16511772
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
